my account
  Loading... Please wait...


Sort by
  • AG-490 | 133550-30-8 | Structure | Supplier
    AG-490 (133550-30-8) is a potent inhibitor of the JAK-2 tyrosine kinase. In acute lymphoblastic leukemia (ALL) cells, which abundantly express JAK-2, AG-490 dose-dependently blocked cell growth, induced apoptosis and...

  • Lestaurtinib | FLT3/TrkA inhibitor
    Lestaurtinib (111358-88-4) is a potent and selective FLT3 inhibitor (IC50= 2 nM).1,2 Inhibits RET and RET phosphorylation in medullary thyroid carcinoma cells.3 Suppresses JAK2/STAT5 signaling and the proliferation of...

  • Niclosamide | STAT3 signaling inhibitor
    Niclosamide (50-65-7) reversibly inhibits mTORC1 signaling and stimulates autophagy1. Inhibits activation and nuclear translocation of STAT3 selectively over STAT1 and STAT5. Niclosamide inhibits transcription of STAT3...

  • Stattic | STAT3 inhibitor
    Stattic (19983-44-9) is a STAT3 inhibitor that inhibits binding of tyrosine-phosphorylated peptides to STAT3 SH2 domain and inhibiting STAT3 activation, dimerization and nuclear translocation1. Displays selectivity over...

  • Tofacitinib | JAK inhibitor
    Tofacitinib (477600-75-2) is a JAK3 inhibitor, currently in clinical use. References/Citations1) Beavo et al. (1970), Effects of xanthine derivatives on lipolysis and on adenosine 3',5'-monophosphate phosphodiesterase...

Share Focus

Connect with Focus